TokenPost·
Incyte Drops Plans for Phase 3 MAESTRA-3 Ovarian Cancer Trial
The study was designed to test INCB123667 with bevacizumab as first-line maintenance therapy for ovarian cancer.
More news
- TokenPostInsight Molecular Diagnostics to Report Q3 Results Nov. 16
- CryptoPotatoTSMC Confirms Employee Data Leak as Hackers Try to Sell 46,000 Records for Bitcoin
- TokenPostGMX Dollar Vault LPs Can Borrow USDG Against GLV on Morpho
- TokenPostBri-Chem Names CFO Tony Pagnucco as Chief Operating Officer
- TokenPostIM Cannabis Reports $1.65 Million in Q3 Revenue and GAAP EPS of -$6.69
- The DefiantNvidia Approached Arm CEO Haas in Search, FT Reports